Title: Finally An Osteoporosis Prescription That Will Help Inhibit Bone Loss

Amgen NASDAQ: AMGN pharmaceutical powerhouse just announced positive performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial. Learn reached primary endpoint of Diminishing new vertebral fractures & secondary endpoints of decreasing time to first non-vertebral & hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation Stated, " I am particularly excited about these findings for the reason that they indicate that denosumab may offer an important new option for patients. " Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an important regulator of osteoclasts (these are the cells that break the bone down) . Denosumab is being considered for its potential to inhibit all stages of osteoclast activity by a targeted mechanism. Denosumab is being researched in a range of bone loss illnesses including rheumatoid arthritis, postmenopausal osteoporosis, & cancer treatment-induced bone loss in breast cancer & prostate cancer patients| in prostate cancer & breast cancer patients as well as for its adequacy to defer bone metastases & inhibit & treat bone destruction across a lot of stages of cancer. Often referred to as the "silent epidemic", osteoporosis is a world wide problem illness that is growing in dominance as the population of the world both increases & ages. WHO, The World Health Organization has just claimed osteoporosis as a significant health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical industry to help combat this terrible disease. According to Amgen the economic burden of osteoporosis is referred to as the "silent epidemi' to that of other major chronic diseases; for example, in the U. S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease & asthma (i )( ii )( iii) . It has been reported that osteoporosis results in more hospice bed-days than stroke, myocardial infarction or breast cancer (iv) . Clinical pharmacist have been developing prescriptions drugs to help patient who experience serious side effects. These products are developed almost at the same time as the medications that aid in the treatment of the primary illness. The fact that research is available to help predict the possible effects & interactions drugs have with each other is outstanding. There are several drugs that both, prevent & treat osteoporosis. Some medicines slow the rate of bone loss or increase bone thickness. Minute amounts of new bone growth may reduce the danger of breaking bones. It is important that you take vitamin D & calcium, exercise & eat well when you take osteoporosis prescriptions.